Merck & Co., Inc.

MRK

Held by 3 specialist biotech funds

High Convergence

3 funds opened new positions. Next phase2 readout (Tulisokibart): Apr 2026. Short interest: 1.1% of float.

Drug Manufacturers - GeneralCEO: Robert DavisIPO: 1978Website ↗

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Recent News & Research

PubMed

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies.

# Investment Summary: Nemtabrutinib Pharmacokinetic Study Merck's nemtabrutinib exposure-response analysis establishes dose optimization parameters that could support regulatory submissions and enable more precise patient dosing in hematologic malignancies, potentially improving efficacy and reducing toxicity-related discontinuations. The population pharmacokinetic modeling provides clinical evidence for dose individualization strategies, which may enhance competitive positioning against other Bruton tyrosine kinase (BTK) inhibitors in a crowded market segment. These findings could facilitate label expansion discussions with regulators and improve commercial uptake by demonstrating improved tolerability and efficacy profiles compared to fixed-dosing competitors.

May 1, 2026

PubMed

Impact of Belzutifan on Pancreatic Cystic Lesions and Neuroendocrine Tumors in Patients With Von Hippel-Lindau Disease.

# Investment Summary: Belzutifan in VHL-Associated Pancreatic Disease Belzutifan (Welireg), Merck's HIF-2α inhibitor approved for VHL disease, demonstrates efficacy in managing pancreatic cystic lesions and neuroendocrine tumors—previously unaddressed complications that significantly impact patient morbidity and surveillance burden. This data expands the drug's clinical utility within the VHL population beyond renal cell carcinoma, potentially improving label claims and patient retention by addressing previously untreatable manifestations. The finding strengthens Welireg's market position in the rare disease space by establishing broader organ-system benefit, though the small addressable market and existing competitive landscape may limit incremental revenue impact.

May 1, 2026

PubMed

Belzutifan Attenuates Choroidal Neovascularization by Suppressing the HIF-2α/PAI-1 Axis.

# Investment Summary: Belzutifan Ophthalmology Potential **Clinical/Commercial Relevance:** This preclinical study demonstrates that belzutifan (Merck's HIF-2α inhibitor, approved for renal cell carcinoma) may have therapeutic activity in choroidal neovascularization (CNV), a leading cause of vision loss in age-related macular degeneration (AMD). The mechanism—HIF-2α/PAI-1 axis suppression—suggests a potential new indication in a large ophthalmic market where current therapies have unmet needs. If validated clinically, this could represent a meaningful label expansion opportunity for an already-approved asset with established safety data, though the pathway from preclinical findings to regulatory approval remains lengthy and uncertain. **Investor Considerations:** The commercial upside depends on clinical trial initiation and efficacy in human subjects

Apr 15, 2026

Merck & Co., Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links

Related Research